Infection control: the case for horizontal rather than vertical interventional programs  by Wenzel, Richard P. & Edmond, Michael B.
International Journal of Infectious Diseases 14S4 (2010) S3–S5Infection control: the case for horizontal rather than vertical interventional
programs
Richard P. Wenzel *, Michael B. Edmond
Department of Internal Medicine, Virginia Commonwealth University, 1101 East Broad Street, PO Box 980663, Richmond, VA 23298, USA
S U M M A R Y
The authors deﬁne two types of infection control interventions: horizontal, in which all infections at any
site are reduced; and vertical, in which only speciﬁc organisms are targeted. We suggest that horizontal
programs should form the platform of all infection control programs and the key question should be,
what is the incremental value of a new vertical program?
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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In developed countries, 5–10% of hospitalized patients encoun-
ter an infection that was not present or incubating on admission. In
the USA, with 35 million admissions annually to acute care
institutions, that percentage translates to 1.75–3.5 million
infections, of which 10% each (175 000–350 000) involve both
the bloodstream and the lung.1–5 The crude mortality of both
nosocomial bloodstream infections and pneumonias is approxi-
mately 25–30% (43 750–105 000 deaths in each category). The
proportion of the deaths directly linked to the infection after
accounting for themortality of the underlying diseases is called the
attributable mortality.6 With bloodstream infections, approxi-
mately one half of the deaths are directly attributable to the
infection (21 875–52 500 deaths).3,4 With nosocomial pneumo-
nias, approximately one third of the deaths are directly attribut-
able to the infection (14 328–34 650 deaths).5 Thus, the morbidity
and mortality are substantial for bloodstream infections and
nosocomial pneumonias.
In developing countries with limited resources and in some
cases with limited expertise, nosocomial infection rates are two- to
three-fold higher than those found in developed nations. Even in
developed countries, new pressures to minimize expenditures for
infection control have followed the reaction to the global recession.
As a result, an intensely focused attention on efﬁcient, evidence-
based programs dominates the thinking of hospital administrators.
2. Controversial issue: horizontal vs. vertical programs
In general two epidemiological approaches exist for infection
control: (1) broad programs which attempt to reduce the rates of* Corresponding author. Tel.: +1 804 828 3389; fax: +1 804 828 5566.
E-mail address: rwenzel@mcvh-vcu.edu (R.P. Wenzel).
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focusing on a single pathogen or single anatomic site. The former
are referred to as ‘horizontal’ programs and the latter as
‘vertical’.7,8 There is strong debate in the infection control arena
about which is the more beneﬁcial approach. An example of the
focus of controversy is the strong advocacy by some infection
control experts for methicillin-resistant Staphylococcus aureus
(MRSA) nasal screening of inpatients (vertical program)9 vs. amore
broad-based horizontal program.7,8
This paper will summarize the current level of evidence for
programs advocated in infection control and explore the relative
merits of horizontal and vertical programs.
2.1. Grading evidence
In 1988, the Agency for Healthcare Research and Quality
(AHRQ)10 designated three levels of evidence of scientiﬁc data for
decision-making: high or ‘A’ – evidence based on randomized
controlled clinical trials or meta-analyses; medium or ‘B’ –
evidence based on well-designed, non-randomized clinical trials
or data from cohorts or case–control studies; and low or ‘C’
(Figure 1).
Looking back approximately 160 years to Vienna and the critical
observationsmade by Ignaz Semmelweis, recall that he showed an
8% mortality from puerperal sepsis among women delivered by
physicians andmedical students and a 2%mortality amongwomen
delivered by midwives.11 Linking the increased mortality among
the former causally to the poor infection control by physicians and
their students, Semmelweis – prior to the Germ Theory era –
surmised that the practice of performing gross autopsies led to
contaminated physician hands (with group A streptococci) who
then examined women who were actively in labor. After the
introduction of handwashing on the wards, the mortality among
women who were delivered by physicians fell dramatically to
1.3%.11 Semmelweis’ paper is thought by many to be the mostses. Published by Elsevier Ltd. All rights reserved.
[(Figure_1)TD$FIG]
Figure 1. The general classiﬁcation of the Agency for Healthcare Research and
Quality depending on the type of study design.
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Figure 2. A conceptual image of a vertical program such as one focusing on
Staphylococcus aureus or MRSA vs. one focusing on all organisms causing
healthcare-associated infections including all S. aureus, all enterococci, all
Candida species, and all Gram-negative rods. The yellow area focusing on MRSA
represents a vertical program. The pink area encompassing all pathogens represents
a horizontal program. (MRSA = methicillin-resistant S. aureus; VRE = vancomycin-
resistant enterococci; GNR = Gram-negative rods.).
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criteria, it would receive only a ‘B’ grade for quality, since it was a
well designed cohort but not a randomized, controlled trial.
In 1941, Skinner and Keefer in their classic article on S. aureus
bloodstream infections prior to the antibiotic era12 showed an 82%
crude mortality among the 122 consecutive cases. Subsequently,
with the introduction of penicillin and early recognition by
Abraham and Chain of a penicillinase-producing bacterium,13
concern about antibiotic-resistant organisms grew. Then in 1959,
Abboud and Waisbren showed that none of 52 patients with S.
aureus bacteremia survived if the minimum inhibitory concentra-
tion (MIC) was 6mg/ml ‘‘despite massive doses of penicillin’’, yet
those withMICs<6mg/ml had a survival rate of 69% (20/29)14. The
latter papers were important in estimating the impact of penicillin
(18% survival without penicillin12 and 69% survival with penicil-
lin14): a 51% absolute difference, the attributable life-saving effect.
Thus, the data show that the new antibioticworkedwell, but only if
the organism was susceptible! These impressive data, however,
would receive a ‘B’ grade – essentially non-randomized cohorts
stratiﬁed by MIC ranges.
More recently, two studies that have measured the bundled
effect of incorporating grade ‘A’ evidence into large cohorts, have
shown the value of evidence-based infection control. In a
prospective study of patients in 103 intensive care units (ICUs),
Pronovost and colleagues insisted on the adherence to ﬁve
evidence-based interventions and subsequently examined cathe-
ter-related bloodstream infections. The authors showed a 66%
reduction of bloodstream infections after 1981 ICU-months of
observation.15 A smaller study at a single institution extended the
concept of bundling evidence-based practices and showed a 40% or
greater reduction in device-related bloodstream infections, cathe-
ter-associated urinary tract infections, and ventilator-associated
pneumonias in the medical, neuroscience, and surgical ICUs.16
These two studies with the most impressive infection control data
recently reported would also receive a ‘B’ grade by the AHRQ
system because they are large cohort observations, even though
they each utilized components of ‘A’ grade evidence.
The conclusion that one could draw is that for many key studies
that have inﬂuenced the practice of infectious diseases and the
discipline of infection control, the data would generate a ‘B’ grade.
In our ownminds we could create designs for ‘A’ grade studies, but
so far these are generally lacking in experimental designs.
2.2. Horizontal vs. vertical intervention
If one imagines the key bloodstream organisms that concern
infection control personnel, they include S. aureus, enterococci,Candida and selected Gram-negative rods. Within each there is a
subset of especially worrisome, resistant pathogens: MRSA,
vancomycin-resistant enterococci (VRE), ﬂuconazole-resistant
Candida species such as some C. glabrata, and multidrug-resistant
Pseudomonas aeruginosa and Acinetobacter species7 (Figure 2).
2.3. Cohorts: screening for MRSA
In two recently published cohorts, MRSA screening in several
hospitals17,18 and in a national program19 have subsequently led to
a marked reduction in MRSA infections. Both impressive cohorts
would receive a ‘B’ grade for evidence. In other cohorts, there have
been mixed results.20,21 A very important point is that no hospital
with a vertical (MRSA) approach has shown a major reduction in
the rate of all infections or of all bloodstream infections.
A recent analysis suggested why theMRSA (vertical) program is
a ﬂawed approach: the favorable outcomes of a horizontal program
dwarf the vertical program in terms of reduced mortality, years of
life lost, and costs.7 In most hospitals, MRSA comprise 14% of all
nosocomial infections. There are also new concerns related to the
biology of S. aureus and nosocomial community-acquired MRSA
(CA-MRSA): throat carriage only of S. aureus has been shown in 25%
of carriers, and MRSA throat-carriage only in 13–15% of
carriers.22,23 Moreover, in a prospective cohort of carriers or
infected patients with CA-MRSA, the organism was found in the
nares in only 41%.24 Thus, nasal screening will fail frequently with
this emerging nosocomial pathogen.
A fair question is, Is there any value to MRSA screening? A
recent meta-analysis suggests that for preoperative carriers of
non-MRSA S. aureus, screening followed by decolonization would
prevent S. aureus surgical site infections.25 Thus, currently it is
reasonable to screen patients undergoing high-risk procedures
such as orthopedic implants and cardiac surgery.
2.4. The role of evidence
Not all authors subscribe to the high value of randomized,
controlled trials. In a recent editorial Berwick says that randomized
controlled trials are ‘‘. . .. inadequate. . .. for studying complex
unstable, nonlinear social change’’.26 Such statements reﬂect the
social attitudes of the ‘post-modern’ era in which science,
technology and medicine are not so highly valued as they were
in the era that sociologists refer to as ‘modernity’. Currently, there
is much value placed on ideology, individual concepts, and rapid
change. Edmond has recently contrasted the differing perspectives
R.P. Wenzel, M.B. Edmond / International Journal of Infectious Diseases 14S4 (2010) S3–S5 S5of hospital epidemiology (which emerged in the era of modernity)
and quality improvement (which emerged in the current post-
modern era).27
3. Conclusions
The key point is that the level of evidence on which most
infection control policy is generated is not grade ‘A’ but grade ‘B’.
Nevertheless, we use the best evidence we have to craft policy,
recognizing principal goals, costs, and adverse events.
The future of infection control will rely on a platform of strong
horizontal programs committed to repeatedly reducing infections
by 50% every 3–4 years. The critical infection control question that
must be addressed before an institution invests new resources for a
vertical program is this:What is its incremental value above that of
the existing horizontal program?
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